Expertise in
15
conditions
Expertise in
15
conditions

Overview

Michael Richards is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Minneapolis, Minnesota. Dr. Richards is highly rated in 15 conditions, according to our data. His top areas of expertise are Hepatoblastoma, Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Richards is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 56 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatrics
Pediatric Hematology Oncology
Licenses
Pediatrics in MN
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica

Locations

2525 Chicago Avenue South, Childrens Specialty Clinic Hematology Oncology Mpls, Minneapolis, MN 55404
612-813-5940

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


56 Clinical Trials

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
View 49 Less Clinical Trials
Similar Doctors
Paul J. Orchard
Expertise in
16
conditions
Pediatric Hematology Oncology | Pediatrics | Hematology
Expertise in
16
conditions
Pediatric Hematology Oncology | Pediatrics | Hematology

Center For Pediatric Blood And Marrow Transplantation - Pediatric Specialty Care Journey Clinic

2450 Riverside Ave, 
Minneapolis, MN 
 (1.2 mi)
Languages Spoken:
English

Paul Orchard is a Pediatric Hematologist Oncologist and a Pediatrics specialist in Minneapolis, Minnesota. He has been an author on 166 peer reviewed articles and participated in 18 clinical trials in the past 15 years. He is licensed to treat patients in MN. Dr. Orchard is highly rated in 16 conditions, according to our data. His top areas of expertise are Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Bone Marrow Transplant, and Osteotomy.

Expertise in
15
conditions
Pediatric Hematology Oncology | Pediatrics
Expertise in
15
conditions
Pediatric Hematology Oncology | Pediatrics
420 Delaware St Se, 
Minneapolis, MN 
 (1.5 mi)
Languages Spoken:
English
Accepting New Patients

Troy Lund is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Minneapolis, Minnesota. Dr. Lund is highly rated in 15 conditions, according to our data. His top areas of expertise are Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Glucose-6-Phosphate Dehydrogenase Deficiency, and Bone Marrow Transplant. Dr. Lund is currently accepting new patients.

Bruce R. Blazar
Expertise in
7
conditions
Pediatric Hematology Oncology | Pediatrics
Expertise in
7
conditions
Pediatric Hematology Oncology | Pediatrics
516 Delaware Street Se, University Of Mn Physicians, Pwb Fifth Floor, Clinic 5b, 
Minneapolis, MN 
 (1.6 mi)
Languages Spoken:
English
Accepting New Patients

Bruce Blazar is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Minneapolis, Minnesota. Dr. Blazar is highly rated in 7 conditions, according to our data. His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Leukemia, Fanconi Anemia, and Bone Marrow Transplant. Dr. Blazar is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile